Ketamine infusion therapy study for veterans with PTSD

December 5, 2016

Klarisana is currently enrolling subjects in a study to measure the effects of ketamine infusions on the severity of symptoms of post-traumatic stress disorder (PTSD) in combat veterans. Eligible veterans will undergo a medical and psychological screening interview, physical examination, and review of their medical history.

If selected, research participants will be given standard questionnaires to assess the symptoms of PTSD, depression, and to evaluate the veteran’s use of alcohol and recreational drugs. They will then undergo the standard induction series of six, one-hour infusions of low-dose ketamine. After the induction series, the veteran will be asked to fill out the screening surveys again at the end of the infusions.

Eligibility Requirements For Ketamine Study

To be eligible, subjects must be men or women between the ages of 18-70, must be combat veterans of the U.S. Military (must provide DD214), must have a diagnosis of, and disability rating for PTSD, by the Department of Veterans Affairs (medical records required). The PTSD must be thought to have been caused by the combat experience and the potential veteran and/or his/her family must subjectively feel that it is affecting the veteran’s everyday life. The veteran must not be currently enrolled in any other studies involving investigational medications or investigational treatments for PTSD. Additionally, the veteran must not be taking any monoamine oxidase inhibitors, must not be taking lamotrigine (Lamictal), must not have congestive heart failure or any uncontrolled blood pressure, must not have a diagnosis of psychosis, must not be in the manic phase of bipolar disorder.

Veterans interested in ketamine infusions are encouraged to contact Klarisana either by phone at 210-556-1430 or by email at

The principal investigator, Dr. Carl J. Bonnett, reserves the right to exclude a potential subject if, after the history and physical examination, any factors come to light which would make ketamine therapy inappropriate for a given patient.

Subscribe to our newsletter

Get updated with the latest news.